Multiple research results from innovent's general biomedicine pipeline to be showcased at the ada 85th scientific sessions

San francisco and suzhou, china , june 21, 2025 /prnewswire/ -- innovent biologics, inc. ("innovent") (hkex: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas, announced that multiple exploratory mechanism-of-action (moa) analyses of mazdutide (investigator-initiated trials) as well as a preclinical study of ibi3030 (pcsk9-ggg antibody-peptide-conjugate) will be showcased at the american diabetes association's (ada) 85th scientific sessions. details are listed below： title: a novel antibody-peptide conjugate targeting pcsk9, glp-1r, gcgr, gipr improves cardiovascular risk markers in preclinical study abstract number ：1886-lb presentation form: poster presentation time: sunday, june 22, 2025.
GM Ratings Summary
GM Quant Ranking